| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f4432a43459a5de46f4a04b577898fd0 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-424
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7036
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-12 |
| filingDate |
2002-02-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2005-02-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e1cc333ad833cbc81ff56e8c71f3715
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6961a18875a84def700a2d099a32d26a |
| publicationDate |
2005-02-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-6852689-B2 |
| titleOfInvention |
Methods for administration of antibiotics |
| abstract |
The invention provides methods for administering a therapeutically effective amount of daptomycin while minimizing skeletal muscle toxicity. The methods provide daptomycin administration at a dosing interval of 24 hours or greater. This long dosing interval minimizes skeletal muscle toxicity and allows for higher peak concentrations of daptomycin, which is related to daptomycin's efficacy. The invention also provides methods of administering lipopeptide antibiotics other than daptomycin while minimizing skeletal muscle toxicity by administering a therapeutically effective amount of the lipopeptide antibiotic at a dosage interval that does not result in muscle toxicity. The invention also provides methods of administering quinupristin/dalfopristin while minimizing skeletal muscle toxicity by administering a therapeutically effective amount of quinupristin/dalfopristin at a dosage interval that dos not result in muscle toxicity. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8604164-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011207658-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009197799-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10647746-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8853357-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8129342-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013149121-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8846610-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9358267-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013059610-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008051326-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9138456-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8697638-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010075215-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11667674-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8796224-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010184649-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8507647-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2674437-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010041589-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8835382-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9662397-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8461188-B2 |
| priorityDate |
1998-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |